NASDAQ:GALT - Galectin Therapeutics Inc. Common Stock Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.16 -0.46 (-9.96 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$4.16
Today's Range$4.12 - $4.60
52-Week Range$1.28 - $6.74
Volume614,002 shs
Average Volume618,257 shs
Market Capitalization$171.32 million
P/E Ratio-8.49
Dividend YieldN/A
Beta2.53

About Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Galectin Therapeutics Inc. Common Stock logoGalectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Debt-to-Equity RatioN/A
Current Ratio2.05
Quick Ratio2.05

Price-To-Earnings

Trailing P/E Ratio-8.49
Forward P/E Ratio-8.32
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.22) per share
Price / Book-18.91

Profitability

EPS (Most Recent Fiscal Year)($0.49)
Net Income$-16,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-244.78%

Miscellaneous

Employees7
Outstanding Shares37,570,000

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics Inc. Common Stock's stock symbol?

Galectin Therapeutics Inc. Common Stock trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics Inc. Common Stock's earnings last quarter?

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) released its earnings results on Friday, May, 11th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View Galectin Therapeutics Inc. Common Stock's Earnings History.

When is Galectin Therapeutics Inc. Common Stock's next earnings date?

Galectin Therapeutics Inc. Common Stock is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Galectin Therapeutics Inc. Common Stock.

What price target have analysts set for GALT?

3 Wall Street analysts have issued 12-month target prices for Galectin Therapeutics Inc. Common Stock's stock. Their forecasts range from $5.00 to $12.00. On average, they expect Galectin Therapeutics Inc. Common Stock's stock price to reach $8.3333 in the next twelve months. View Analyst Ratings for Galectin Therapeutics Inc. Common Stock.

Are investors shorting Galectin Therapeutics Inc. Common Stock?

Galectin Therapeutics Inc. Common Stock saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,510,306 shares, an increase of 49.7% from the March 30th total of 1,676,645 shares. Based on an average daily trading volume, of 609,378 shares, the days-to-cover ratio is currently 4.1 days. Currently, 8.3% of the shares of the stock are short sold.

Who are some of Galectin Therapeutics Inc. Common Stock's key competitors?

Who are Galectin Therapeutics Inc. Common Stock's key executives?

Galectin Therapeutics Inc. Common Stock's management team includes the folowing people:
  • Dr. Peter G. Traber, CEO, Pres & Chief Medical Officer (Age 63)
  • Mr. Jack W. Callicutt CPA, Chief Financial Officer (Age 51)
  • Dr. Harold H. Shlevin Ph.D., COO & Corp. Sec. (Age 68)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer Ph.D., VP of Discovery Research & Product Devel. (Age 71)

Has Galectin Therapeutics Inc. Common Stock been receiving favorable news coverage?

News headlines about GALT stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galectin Therapeutics Inc. Common Stock earned a coverage optimism score of 0.03 on Accern's scale. They also gave news coverage about the company an impact score of 48.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Galectin Therapeutics Inc. Common Stock's major shareholders?

Galectin Therapeutics Inc. Common Stock's stock is owned by a variety of of retail and institutional investors. Top institutional investors include D.A. Davidson & CO. (1.95%), Benchmark Capital Advisors (0.59%), Millennium Management LLC (0.25%), Tibra Equities Europe Ltd (0.17%), A.R.T. Advisors LLC (0.15%) and LPL Financial LLC (0.06%). Company insiders that own Galectin Therapeutics Inc. Common Stock stock include Fund LP 10X, Jack W Callicutt, James C Czirr, Kevin D Freeman, Marc Rubin and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics Inc. Common Stock.

Which major investors are buying Galectin Therapeutics Inc. Common Stock stock?

GALT stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tibra Equities Europe Ltd, D.A. Davidson & CO., Benchmark Capital Advisors, LPL Financial LLC, A.R.T. Advisors LLC and Laurel Wealth Advisors Inc.. Company insiders that have bought Galectin Therapeutics Inc. Common Stock stock in the last two years include Kevin D Freeman, Marc Rubin and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics Inc. Common Stock.

How do I buy shares of Galectin Therapeutics Inc. Common Stock?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics Inc. Common Stock's stock price today?

One share of GALT stock can currently be purchased for approximately $4.16.

How big of a company is Galectin Therapeutics Inc. Common Stock?

Galectin Therapeutics Inc. Common Stock has a market capitalization of $171.32 million. The company earns $-16,230,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Galectin Therapeutics Inc. Common Stock employs 7 workers across the globe.

How can I contact Galectin Therapeutics Inc. Common Stock?

Galectin Therapeutics Inc. Common Stock's mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics Inc. Common Stock (GALT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics Inc. Common Stock and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Galectin Therapeutics Inc. Common Stock in the last 12 months. Their average twelve-month price target is $8.3333, suggesting that the stock has a possible upside of 100.32%. The high price target for GALT is $12.00 and the low price target for GALT is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.752.75
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.3333$7.6667$6.25$4.6250
Price Target Upside: 100.32% upside75.04% upside42.69% upside84.26% upside

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Consensus Price Target History

Price Target History for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018HC WainwrightBoost Price TargetBuy$12.00HighView Rating Details
1/4/2018Roth CapitalBoost Price TargetBuy$3.00 ➝ $8.00MediumView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/AView Rating Details
4/3/2017FBR & CoReiterated RatingMarket Perform$2.00MediumView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Earnings History and Estimates Chart

Earnings by Quarter for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181($0.11)($0.11)($0.11)

Galectin Therapeutics Inc. Common Stock (NASDAQ GALT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
5/11/2018Q1 2018($0.13)($0.12)ViewN/AView Earnings Details
3/29/2018Q4 2017($0.11)($0.0730)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.17)($0.13)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.22)($0.19)ViewN/AView Earnings Details
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
3/18/2015Q4 2014($0.17)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
3/29/2013Q4 2012($0.20)($0.17)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.15)($0.19)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.21)($0.17)ViewN/AView Earnings Details
3/30/2012Q4 2011($0.18)($0.29)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.24)($0.19)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.18)($0.34)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.18)($0.24)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.12)ViewN/AView Earnings Details
11/12/2010Q3 2010($0.12)($0.20)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.28)ViewN/AView Earnings Details
5/12/2010Q1 2010($0.34)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.13)ViewN/AView Earnings Details
11/13/2009Q3 2009($0.24)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.40)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.36)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.17)ViewN/AView Earnings Details
11/7/2008Q3 2008$0.03ViewN/AView Earnings Details
8/8/2008Q2 2008($0.06)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.21)ViewN/AView Earnings Details
3/28/2008Q4 2007($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Galectin Therapeutics Inc. Common Stock (NASDAQ GALT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 45.20%
Institutional Ownership Percentage: 12.47%
Insider Trading History for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)
Institutional Ownership by Quarter for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Galectin Therapeutics Inc. Common Stock (NASDAQ GALT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Theodore Daniel ZucconiDirectorSell4,000$3.58$14,320.005,083View SEC Filing  
4/4/2018Jack W CallicuttCFOSell3,349$5.00$16,745.004,609View SEC Filing  
2/1/2018Kevin D FreemanDirectorBuy2,000$4.10$8,200.0022,043View SEC Filing  
1/26/2018Fund L.P. 10XMajor ShareholderSell244,444$5.43$1,327,330.92View SEC Filing  
1/25/2018James C CzirrDirectorSell205,144$5.45$1,118,034.80View SEC Filing  
12/8/2017Marc RubinDirectorBuy7,000$1.85$12,950.0055,581View SEC Filing  
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.001,083View SEC Filing  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52109,445View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Galectin Therapeutics Inc. Common Stock (NASDAQ GALT) News Headlines

Source:
DateHeadline
Seaport Global Securities Research Analysts Increase Earnings Estimates for Galectin Therapeutics Inc. (GALT)Seaport Global Securities Research Analysts Increase Earnings Estimates for Galectin Therapeutics Inc. (GALT)
www.americanbankingnews.com - May 17 at 7:14 AM
Zacks: Analysts Expect Galectin Therapeutics Inc. (GALT) to Post -$0.13 EPSZacks: Analysts Expect Galectin Therapeutics Inc. (GALT) to Post -$0.13 EPS
www.americanbankingnews.com - May 16 at 3:29 PM
Q2 2018 Earnings Estimate for Galectin Therapeutics Inc. Issued By Seaport Global Securities (GALT)Q2 2018 Earnings Estimate for Galectin Therapeutics Inc. Issued By Seaport Global Securities (GALT)
www.americanbankingnews.com - May 16 at 7:16 AM
HC Wainwright Boosts Galectin Therapeutics (GALT) Price Target to $12.00HC Wainwright Boosts Galectin Therapeutics (GALT) Price Target to $12.00
www.americanbankingnews.com - May 15 at 1:19 PM
Galectin Therapeutics (GALT) Rating Increased to Hold at ValuEngineGalectin Therapeutics (GALT) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 15 at 1:15 PM
Today’s Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin TherapeuticsToday’s Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin Therapeutics
finance.yahoo.com - May 15 at 8:25 AM
Galectin Therapeutics (GALT) Says it Will Proceed with Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA MeetingGalectin Therapeutics (GALT) Says it Will Proceed with Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
www.streetinsider.com - May 14 at 9:45 AM
Galectin to advance NASH candidate GR-MD-02 into Phase 3Galectin to advance NASH candidate GR-MD-02 into Phase 3
seekingalpha.com - May 14 at 9:45 AM
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA MeetingGalectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
finance.yahoo.com - May 14 at 9:45 AM
Galectin Therapeutics (GALT) Posts  Earnings Results, Beats Expectations By $0.01 EPSGalectin Therapeutics (GALT) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 11:15 AM
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business UpdateGalectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 5:42 PM
Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.comPulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.com
www.businesswire.com - May 10 at 8:34 AM
ValuEngine Upgrades Galectin Therapeutics (GALT) to "Sell"ValuEngine Upgrades Galectin Therapeutics (GALT) to "Sell"
www.americanbankingnews.com - May 4 at 12:52 AM
 Analysts Anticipate Galectin Therapeutics Inc. (GALT) to Announce -$0.13 EPS Analysts Anticipate Galectin Therapeutics Inc. (GALT) to Announce -$0.13 EPS
www.americanbankingnews.com - April 29 at 3:10 AM
Galectin Therapeutics Inc. (GALT) Short Interest UpdateGalectin Therapeutics Inc. (GALT) Short Interest Update
www.americanbankingnews.com - April 28 at 2:28 AM
Galectin Therapeutics (GALT) Cut to Strong Sell at ValuEngineGalectin Therapeutics (GALT) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 25 at 12:58 AM
Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with DyskinesiaBlog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with Dyskinesia
finance.yahoo.com - April 23 at 9:00 AM
Galectin Therapeutics Inc (GALT) Director Sells $14,320.00 in StockGalectin Therapeutics Inc (GALT) Director Sells $14,320.00 in Stock
www.americanbankingnews.com - April 18 at 8:14 PM
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
finance.yahoo.com - April 18 at 8:46 AM
Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces andGalectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and
www.nasdaq.com - April 16 at 9:15 AM
Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH CirrhosisGalectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
finance.yahoo.com - April 16 at 9:15 AM
Galectin Therapeutics (GALT) Downgraded by ValuEngineGalectin Therapeutics (GALT) Downgraded by ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM
ValuEngine Lowers Galectin Therapeutics (GALT) to SellValuEngine Lowers Galectin Therapeutics (GALT) to Sell
www.americanbankingnews.com - April 13 at 11:10 PM
-$0.13 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter-$0.13 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter
www.americanbankingnews.com - April 12 at 3:18 AM
Galectin Therapeutics (GALT) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowGalectin Therapeutics (GALT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 5:22 PM
Galectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in StockGalectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in Stock
www.americanbankingnews.com - April 6 at 7:33 PM
Galectin Therapeutics (GALT) to Present Late-Breaker Oral Presentation at The International Liver CongressGalectin Therapeutics (GALT) to Present Late-Breaker Oral Presentation at The International Liver Congress
www.streetinsider.com - April 4 at 4:36 PM
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
finance.yahoo.com - April 4 at 4:35 PM
ValuEngine Downgrades Galectin Therapeutics (GALT) to SellValuEngine Downgrades Galectin Therapeutics (GALT) to Sell
www.americanbankingnews.com - April 3 at 3:37 PM
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 2 at 5:28 PM
These Biotech Stocks Have a Strong Green Close on FridayThese Biotech Stocks Have a Strong Green Close on Friday
finance.yahoo.com - March 30 at 8:41 AM
Galectin Therapeutics (GALT) Issues  Earnings Results, Beats Expectations By $0.04 EPSGalectin Therapeutics (GALT) Issues Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - March 29 at 2:21 PM
Galectin Therapeutics Reports 2017 Financial Results and Provides Business UpdateGalectin Therapeutics Reports 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 29 at 8:27 AM
Pre-Market Earnings Report for March 29, 2018 : STZ, SAIC, WOR, LNN, ANGO, FINL, MOV, TITN, ALDX, GALT, ALTPre-Market Earnings Report for March 29, 2018 : STZ, SAIC, WOR, LNN, ANGO, FINL, MOV, TITN, ALDX, GALT, ALT
www.nasdaq.com - March 28 at 5:19 PM
Galectin Therapeutics (GALT) Upgraded by ValuEngine to HoldGalectin Therapeutics (GALT) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - March 25 at 11:21 AM
Galectin Therapeutics (GALT) to Release Earnings on ThursdayGalectin Therapeutics (GALT) to Release Earnings on Thursday
www.americanbankingnews.com - March 22 at 1:14 AM
Galectin Therapeutics Inc (GALT) Receives Average Rating of "Buy" from AnalystsGalectin Therapeutics Inc (GALT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 11:56 AM
Galectin Therapeutics (GALT) Presents At 30th Annual ROTH Conference - SlideshowGalectin Therapeutics (GALT) Presents At 30th Annual ROTH Conference - Slideshow
seekingalpha.com - March 13 at 5:39 PM
Galectin Therapeutics to Present at Two International Conferences in MarchGalectin Therapeutics to Present at Two International Conferences in March
finance.yahoo.com - March 9 at 9:57 AM
Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor ConferenceGalectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
finance.yahoo.com - March 8 at 9:34 AM
Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018
finance.yahoo.com - March 5 at 5:24 PM
Galectin Therapeutics to Present at 30th Annual ROTH ConferenceGalectin Therapeutics to Present at 30th Annual ROTH Conference
finance.yahoo.com - February 28 at 5:29 PM
NASH Pathogenesis: Better Understanding And A Look At Galectin - Seeking AlphaNASH Pathogenesis: Better Understanding And A Look At Galectin - Seeking Alpha
seekingalpha.com - February 22 at 8:24 AM
Galectin Therapeutics Inc (GALT) Given Average Rating of "Buy" by BrokeragesGalectin Therapeutics Inc (GALT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 2:11 PM
-$0.11 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter-$0.11 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter
www.americanbankingnews.com - February 20 at 5:14 AM
Update On Galectin Therapeutics Potential Entry Into Cancer Market - Seeking AlphaUpdate On Galectin Therapeutics' Potential Entry Into Cancer Market - Seeking Alpha
seekingalpha.com - February 16 at 8:13 AM
Galectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - SlideshowGalectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:31 PM
Galectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment ResearchGalectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 7 at 12:06 AM
Galectin Therapeutics to Present at BIO CEO & Investor ConferenceGalectin Therapeutics to Present at BIO CEO & Investor Conference
feeds.benzinga.com - February 6 at 9:27 AM
Zacks: Brokerages Anticipate Galectin Therapeutics Inc (GALT) Will Post Earnings of -$0.11 Per ShareZacks: Brokerages Anticipate Galectin Therapeutics Inc (GALT) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - February 3 at 5:12 AM

SEC Filings

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galectin Therapeutics Inc. Common Stock (NASDAQ GALT) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.